BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
BridgeBio (Nasdaq: BBIO) will present ten moderated digital posters at the American Heart Association Scientific Sessions 2025 in New Orleans, Nov 7–10, 2025. The posters report clinical findings from the ATTRibute-CM study, including data on acoramidis showing reductions in all-cause mortality and cardiovascular hospitalizations, benefits across pre-specified subgroups, effects in the p.V142I (V122I) variant population, and NT-proBNP and quality-of-life improvements.
Presentations are scheduled Nov 8–10 with lead presenters from major centers (University College London, University of Pittsburgh, Cedars-Sinai, Columbia, Stanford, UChicago, U Washington, and others). A separate poster covers vutrisiran real-world healthcare resource use and mortality from a retrospective database analysis.
BridgeBio (Nasdaq: BBIO) presenterà dieci poster digitali moderati durante le Scientific Sessions 2025 dell'American Heart Association a New Orleans, dal 7 al 10 novembre 2025. I poster riportano i risultati clinici dello studio ATTRibute-CM, inclusi dati su acoramidis che mostrano riduzioni della mortalità per tutte le cause e delle ospedalizzazioni cardiovascolari, benefici nei sottogruppi predefiniti, effetti nella popolazione della variante p.V142I (V122I), e miglioramenti di NT-proBNP e della qualità della vita.
Le presentazioni sono in programma dall'8 al 10 novembre con relatori principali provenienti da centri importanti (University College London, University of Pittsburgh, Cedars-Sinai, Columbia, Stanford, UChicago, U Washington e altri). Un poster separato riguarda l'utilizzo delle risorse sanitarie nella vita reale e la mortalità, derivanti da un'analisi retrospettiva di database.
BridgeBio (Nasdaq: BBIO) presentará diez pósters digitales moderados en las Sesiones Científicas 2025 de la American Heart Association en Nueva Orleans, del 7 al 10 de noviembre de 2025. Los pósters reportan hallazgos clínicos del estudio ATTRibute-CM, incluyendo datos sobre acoramidis que muestran reducciones de la mortalidad por todas las causas y de las hospitalizaciones cardiovasculares, beneficios en subgrupos predefinidos, efectos en la población de la variante p.V142I (V122I), y mejoras en NT-proBNP y en la calidad de vida.
Las presentaciones están programadas del 8 al 10 de noviembre con presentadores principales de centros importantes (University College London, University of Pittsburgh, Cedars-Sinai, Columbia, Stanford, UChicago, U Washington y otros). Un póster separado aborda el uso de recursos de atención sanitaria en el mundo real y la mortalidad a partir de un análisis de base de datos retrospectivo.
BridgeBio (Nasdaq: BBIO)는 10개의 중재형 디지털 포스터를 2025년 American Heart Association Scientific Sessions에서 뉴올리언스에서 2025년 11월 7일부터 10일까지 발표합니다. 포스터는 ATTRibute-CM 연구의 임상 결과를 보고하며, acoramidis가 모든 원인 사망률 및 심혈관성 입원 감소를 보여주고, 사전에 정의된 하위군에서의 이점, p.V142I(V122I) 변이군에서의 효과, NT-proBNP 및 삶의 질 개선 등을 포함합니다.
발표는 11월 8일부터 10일까지 주요 센터의 발표자들과 함께 진행되며(University College London, University of Pittsburgh, Cedars-Sinai, Columbia, Stanford, UChicago, U Washington 등), 주요 발표자들이 참석합니다. 별도의 포스터는 재무조사 데이터베이스 분석에서 실제 세계의 의료 자원 사용 및 사망률을 다룹니다.
BridgeBio (Nasdaq : BBIO) présentera dix posters numériques modulés lors des Sessions Scientifiques 2025 de l'American Heart Association à la Nouvelle-Orléans, du 7 au 10 novembre 2025. Les posters présentent des résultats cliniques de l'étude ATTRibute-CM, notamment des données sur acoramidis montrant des réductions de la mortalité toutes causes et des hospitalisations cardiovasculaires, des bénéfices dans des sous-groupes pré-spécifiés, des effets dans la population de la variante p.V142I (V122I), et des améliorations de NT-proBNP et de la qualité de vie.
Les présentations sont prévues du 8 au 10 novembre avec des présentateurs principaux issus de centres majeurs (University College London, University of Pittsburgh, Cedars-Sinai, Columbia, Stanford, UChicago, U Washington et d'autres). Un poster séparé porte sur l'utilisation des ressources de soins de santé dans la vie réelle et la mortalité à partir d'une analyse de base de données rétrospective.
BridgeBio (Nasdaq: BBIO) wird auf den Scientific Sessions 2025 der American Heart Association in New Orleans vom 7. bis 10. November 2025 zehn moderierte digitale Poster präsentieren. Die Poster berichten klinische Ergebnisse der ATTRibute-CM-Studie, einschließlich Daten zu acoramidis, die Reduktionen der Mortalität aller Ursachen und kardiovaskuläre Hospitalisierungen zeigen, Vorteile in vordefinierten Untergruppen, Effekte in der Population der Variantengruppe p.V142I (V122I) sowie Verbesserungen von NT-proBNP und Lebensqualität.
Die Präsentationen finden vom 8. bis 10. November statt, mit Hauptrednern aus führenden Zentren (University College London, University of Pittsburgh, Cedars-Sinai, Columbia, Stanford, UChicago, U Washington und weitere). Ein separates Poster behandelt die reale Nutzung von Gesundheitsressourcen und Mortalität aus einer retrospektiven Datenbankanalyse.
BridgeBio (Nasdaq: BBIO) ستقدّم عشرة ملصقات رقمية معدّلة خلال جلسات الجمعية الأمريكية للقلب 2025 في نيو أورلينز، من 7 إلى 10 نوفمبر 2025. تقارير الملصقات عن نتائج سريرية من دراسة ATTRibute-CM، بما في ذلك بيانات عن acoramidis تُظهر خفض الوفيات الناتجة عن أسباب متعددة وتقليل الإقامات في المستشفيات القلبية الوعائية، وفوائد عبر مجموعات فرعية محددة مسبقاً، وتأثيرات في فئة متغير p.V142I (V122I)، وتحسين NT-proBNP وجودة الحياة.
ستُعقد العروض في الفترة من 8 إلى 10 نوفمبر مع مقدّمين رئيسيين من مراكز كبرى (University College London، University of Pittsburgh، Cedars-Sinai، Columbia، Stanford، UChicago، U Washington وآخرين). ملصق منفصل يغطي استخدام الموارد الصحية في العالم الواقعي والوفيات من تحليل قاعدة بيانات استعادية.
- None.
- None.
PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will be shared at the American Heart Association (AHA) Scientific Sessions 2025, taking place in New Orleans, LA from November 7 - 10, 2025.
Moderated Digital Posters:
Acoramidis Effect on All-Cause Mortality in Patients with p.V142I (V122I) Variant ATTR-CM: Findings from the ATTRibute-CM Study
Presenter: Marianna Fontana, M.D., University College London, UK
Date/time: Saturday, November 8 at 3:15 pm CT
Acoramidis Reduces All-Cause Mortality and First Cardiovascular Hospitalization in Patients with Variant Transthyretin Amyloid Cardiomyopathy: Results from the ATTRibute-CM Study
Presenter: Prem Soman, M.D., Ph.D., University of Pittsburgh School of Medicine, U.S.
Date/time: Saturday, November 8 at 9:15 am CT
Acoramidis Reduces All-Cause Mortality and Cardiovascular-Related Hospitalizations Through Month 42 in Transthyretin Amyloid Cardiomyopathy Across All Pre-specified Patient Subgroups
Presenter: Lily Stern, M.D., Cedars-Sinai Heart Institute, U.S.
Date/time: Saturday, November 8 at 3:15 pm CT
Acoramidis Lowers NT-proBNP in a Larger Proportion of ATTRibute-CM Study Participants with Transthyretin Amyloid Cardiomyopathy Compared with Placebo, Independent of Atrial Fibrillation Status
Presenter: Mathew Maurer, M.D., Columbia University Irving Medical Center, U.S.
Date/time: Saturday, November 8 at 9:15 am CT
Demographic Disparities in Tafamidis Treatment and Clinical Outcomes Across the United States
Presenter: Nicole Cyrille-Superville, M.D., Atrium Health Sanger Heart & Vascular Institute Kenilworth, Charlotte, NC, U.S.
Date/time: Saturday, November 8 at 12:15 pm CT
Geographic Disparities in Transthyretin Amyloid Cardiomyopathy Prevalence in United States Veterans
Presenter: Sandesh Dev, M.D., Southern Arizona VA Health Care System, U.S.
Date/time: Saturday, November 8 at 3:15 pm CT
Serum Transthyretin Levels at Day 28 are Associated with Cardiovascular Outcomes: Insights from the ATTRibute-CM Study
Presenter: Nitasha Sarswat, M.D., UChicago Medicine, U.S.
Date/time: Sunday, November 9 at 3:15 pm CT
Acoramidis Improved Clinical Outcomes, Function, Quality of Life and NT-proBNP in Patients with Transthyretin Amyloid Cardiomyopathy Regardless of Atrial Fibrillation Status at Baseline
Presenter: Richard Cheng, M.D., University of Washington, Seattle, WA, U.S.
Date/time: Sunday, November 9 at 3:15 pm CT
Acoramidis Reduces the Risk of All-Cause Mortality and Cardiovascular-Related Hospitalization Compared with Placebo in Participants with Transthyretin Amyloid Cardiomyopathy and Early-Stage Heart Failure Regardless of Atrial Fibrillation History: Insights from ATTRibute-CM
Presenter: Ronald Witteles, M.D., Stanford University School of Medicine, U.S.
Date/time: Saturday, November 8 at 3:15 pm CT
Vutrisiran Healthcare Resource Utilization, Costs, Discontinuation, and Mortality: A Retrospective Database Analysis
Presenter: Nicole Bart, M.D., Ph.D., St Vincent's Hospital Sydney, AU
Date/time: Monday, November 10 at 10:45 am CT
About Attruby™ (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (
About BridgeBio
BridgeBio Pharma (BridgeBio; Nasdaq: BBIO) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com
FAQ
When will BridgeBio (BBIO) present ATTRibute-CM data at AHA 2025?
Which BBIO presentation covers the p.V142I (V122I) variant and when is it?
Which BBIO poster reports acoramidis effects on mortality and hospitalizations at AHA 2025?
Does the ATTRibute-CM data include biomarker results for BBIO (BBIO)?
Which BBIO presenters report geographic or demographic disparities in ATTR-CM at AHA 2025?
Is there a BBIO presentation on vutrisiran real-world outcomes at AHA 2025?
